In patients treated with ranibizumab during the core study , consecutive individualized ranibizumab treatment during the extension study led to an overall maintenance of BCVA and central retinal subfield thickness ( CRST ) observed at month @ over the @-year extension study ( +@ letters , -@ m -LSB- prior ranibizumab -RSB- and +@ letters , -@ m -LSB- prior ranibizumab + laser -RSB- from baseline at month @ ) with a median of @ injections ( mean , @ injections ; prior ranibizumab ) and @ ( mean , @ injections ; prior ranibizumab + laser ) .